Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes on heart risk: GPT-4o and claude face off against doctors in chest pain study

NCT ID NCT07626060

Diagnosis Sponsor: Marmara University Pendik Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will enroll 690 adults who come to the emergency room with chest pain (not from injury). Researchers will test whether two AI models, GPT-4o and Claude, can correctly calculate a heart risk score (HEART score) from patient notes and predict if a serious heart event will happen within 30 days. The AI's performance will be compared to a consensus score from three emergency medicine doctors. The goal is to see if AI can help speed up and improve heart risk assessment in busy ERs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 690 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of consecutive adult patients presenting with a chief complaint of non-traumatic chest pain to the emergency department of Marmara University Pendik Training and Research Hospital, a tertiary care academic medical center in Istanbul, Turkey. This target population comprises real-world emergency medicine admissions that require acute coronary syndrome risk stratification and evaluation with the HEART score. It excludes individuals presenting with traumatic pain etiologies or acute ST-elevation myocardial infarction (STEMI) requiring immediate, time-critical reperfusion pathways.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: * Age \>=18 years * Chief complaint of non-traumatic chest pain at the emergency department * Written informed consent obtained from the patient or legally authorized representative * Availability for 30-day follow-up (reachable by telephone and/or actively registered in the e-Nabiz national health database) EXCLUSION CRITERIA: * Traumatic chest pain etiology * ST-elevation myocardial infarction (STEMI) at presentation requiring immediate reperfusion protocol * Refusal or subsequent withdrawal of informed consent * Inability to complete the mandatory 30-day follow-up period WITHDRAWAL CRITERIA: * Patient or representative requests data withdrawal after initial consent * Administrative identification of retrospective data entry after enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Emergencies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) Artificial intelligence (AI) in diagnosis Chest pain rule out myocardial infarction Emergency medicine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Marmara University Pendik Training and Research Hospital

    RECRUITING

    Istanbul, Istanbul, 34870, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.